IBB News and Press, iShares Biotechnology ETF From 03/14/23

2023-03-14 02:00:18 ET Summary The private domestic sector balance increased by $190+ billion in February 2023 despite the external sector and bank credit creation headwinds. Bank credit retraction was -$30+ billion as more loans were repaid or written off than were created. T...

2023-03-13 06:00:00 ET Summary The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks. Regulators are expected to take swift action this week to contain the crisis. Treasury yields experienced a sharp...

2023-03-11 04:42:25 ET Summary Fed's aggressive rate hikes, plus SVB crisis, are a big worry right now. Behind the scenes, a (related) biotech stock crisis is also brewing. Market internals remain weak and demand caution going forward. What do a major U.S. commercial...

2023-03-09 02:50:00 ET Summary Rates of change matter, especially for tech companies, and we would expect investors to react favorably to accelerating growth. In healthcare, we continue to find investment opportunities in a difficult macro environment. If the U.S. enters a tra...

2023-03-09 02:20:00 ET Summary Increasing selling pressure among biotech stocks is a major concern. While the market's intermediate-term path is still up, the short-term outlook is weakening. Beware higher volatility in March as healthcare sector selling pressure persists. ...

2023-03-09 00:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

Summary We think healthcare companies are quite resilient during periods of inflation because their products are not substitutable and they deliver innovation. Healthcare has lagged behind many other areas in terms of its adoption of technology. We think, regardless of the market en...

Summary Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS. Merck expects to deploy capital through strategic small bolt-on acquisitions, which we are a big fan of, rather than rampant big indiscriminate acquisitio...

Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren. Warren raises a number of important issues but few that pertain specifically to this deal...